FAQ on Quantum BioPharma Ltd.'s Positive Phase 1 Safety Results for Lucid-MS

What is Lucid-MS?

Lucid-MS is a patented, first-in-class, non-immunomodulatory neuroprotective compound developed by Quantum BioPharma Ltd. targeting multiple sclerosis by preventing demyelination.

What were the results of the Phase 1 trial for Lucid-MS?

The Phase 1 multiple ascending dose trial confirmed no safety or tolerability concerns in healthy participants, supporting advancement to efficacy trials in MS patients.

Why are the Phase 1 results significant for Quantum BioPharma Ltd.?

The positive safety results are a critical step towards advancing Lucid-MS into efficacy trials and preparing for an investigational new drug application with the FDA.

How does Lucid-MS work?

Lucid-MS is designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, as shown in preclinical models.

What is Quantum BioPharma Ltd.’s focus?

Quantum BioPharma is dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, with Lucid-MS as its lead compound for multiple sclerosis.

Where can I find more information about Quantum BioPharma Ltd.?

More information is available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/.

What are the next steps for Lucid-MS?

The next steps include advancing to efficacy trials in MS patients and preparing an investigational new drug application with the FDA.

Does Quantum BioPharma Ltd. have other products or investments?

Yes, Quantum BioPharma has a portfolio including UNBUZZD™ for alcohol misuse disorders and strategic investments through FSD Strategic Investments Inc., among others.